Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2015016729) UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/016729 International Application No.: PCT/PT2014/000052
Publication Date: 05.02.2015 International Filing Date: 01.08.2014
IPC:
C07D 401/12 (2006.01) ,A61K 31/454 (2006.01) ,A61P 11/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
Applicants:
BIAL - PORTELA & Cª, S.A. [PT/PT]; Av. da Siderurgia Nacional P-4745-457 S. Mamede do Coronado, PT
Inventors:
KISS, Laszlo Erno; PT
GUSMÃO DE NORONHA, Rita; PT
ROSA, Carla Patrícia da Costa Pereira; PT
PINTO, Rui; PT
Agent:
MOREIRA, Pedro Alves; PT
Priority Data:
1313903.502.08.2013GB
Title (EN) UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS
(FR) COMPOSÉS D'URÉE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
Abstract:
(EN) There is provided a compound having Formula I:(I) wherein: R1 is aryl which is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy, or R1 is aryl which is substituted with a second aryl group or an aryloxy group, wherein the second aryl group or the aryloxy group is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy; R2 is C1-4 alkyl; R3 is selected from hydroxyl and OSO2CH3; R4 and R5 are independently selected from hydrogen, hydroxyl and halogen; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; wherein when R3 is hydroxyl and R4 and R5 are not hydroxyl, the optionally substituted aryl group, second aryl group or aryloxy group of R1 is substituted with one or more hydroxyl groups or C1-4 alkoxy groups, or wherein when R3 is hydroxyl, one of R4 and R5 is hydroxyl, provided that the compound is not N-(1-benzylpiperidin-4-yl)-4-(3,4-dihydroxyphenyl)-N-methyl-1H-imidazole-1-carboxamide hydrobromide. The compound may be used as an inhibitor of fatty acid amide hydrolase.
(FR) La présente invention concerne un composé de formule I :(I) dans laquelle : R1 représente un aryle qui est éventuellement substitué par un ou plusieurs groupes choisis parmi un hydroxyle, un halogène et un alcoxy en C1-4, ou R1 représente un aryle qui est substitué par un second groupe aryle ou un groupe aryloxy, le second groupe aryle ou le groupe aryloxy étant éventuellement substitué par un ou plusieurs groupes choisis parmi un hydroxyle, un halogène et un alcoxy en C1-4; R2 représente un alkyle en C1-4; R3 est choisi parmi un hydroxyle et OSO2CH3; R4 et R5 sont indépendamment choisis parmi un hydrogène, un hydroxyle et un halogène; et n représente 0 ou 1; ou un sel associé pharmaceutiquement acceptable; sachant que, lorsque R3 représente un hydroxyle et R4 et R5 ne représentent pas un hydroxyle, le groupe aryle, le second groupe aryle ou le groupe aryloxy éventuellement substitués de R1 est substitué par un ou plusieurs groupes hydroxyle ou des groupes alcoxy en C1-4, ou lorsque R3 représente un hydroxyle, R4 ou R5 représente un hydroxyle, à condition que le composé ne soit pas le bromhydrate de N-(1-benzylpipéridin-4-yl)-4-(3,4-dihydroxyphényl)-N-méthyl-1H-imidazole-1-carboxamide. Le composé peut être utilisé comme inhibiteur d'hydrolase d'amides d'acides gras.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)